Search Results

therapeutic developments. Nonetheless, significant controversies remain, and these controversies can cause major disagreement among experts. This issue of JNCCN proves this point and also illustrates the importance that we in the medical community must place

disease response or tumor type: results from a prospective community oncology study. Procrit Study Group . J Clin Oncol 1998 ; 16 : 3412 – 3425 . 10 Gabrilove JL Cleeland CS Livingston RB . Clinical evaluation of once-weekly dosing of

–agnostic approvals that were based on common genetic alterations rather than the tissue of origin. The OCE coordinated work across the various medical product centers throughout the FDA, and with the cancer research community, to make these advancements possible

Community, agreed that navigation and support are critical, because benefits are often difficult for individuals to understand and navigate. Panelists also emphasized the importance of considering long-term rather than just short-term costs when

candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors . Transfusion 2002 ; 42 : 1414 – 1421 . 57 Ofran Y Avivi I Oliven A . Granulocyte transfusions for

centers (7%) offered referral to a community fertility clinic not affiliated with their center. Most (78%) provided services if requested by patients. To a lesser extent, respondents reported sexual health being addressed in the survivorship phase (47%) or

and counseling. 28 Community Education Although panel testing has certainly moved clinical practice forward in many ways, it has also introduced its own set of problems that highlight the need for education of community practitioners on the

designed to streamline cancer diagnosis and treatment. Head and neck cancer (HNC) remains a difficult disease to diagnose and treat. Delivery of multimodality treatment for advanced HNC is challenging at both academic centers and in the community setting

: Flatiron Health electronic health record data, largely from community oncology practices, from January 2011–April 2018 were used for this retrospective observational study. Treatment-naïve (TN) and relapsed/refractory (RR) second-line patients diagnosed

clinicians and on the judgement of experts, in particular. To some extent, the clinical community brought this situation on itself with the variations in care and unnecessary procedure rates that were documented in the late 1980s. Now, unfortunately, the